Capricor Therapeutics, Inc. (CAPR) Stock Overview
Explore Capricor Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Capricor Therapeutics, Inc. (CAPR)
Key Financials
Key Financials
Market Cap
380.5M
P/E Ratio
-2.83
EPS (TTM)
$-2.32
ROE
-0.59%
CAPR Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Capricor Therapeutics, Inc. (NASDAQ: CAPR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Capricor Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CAPR on the NASDAQ shows an RSI of 12.92, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $30.54 for the NASDAQ listing.
Key metrics behind Capricor Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -2.83 and a market capitalization of 380.5M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CAPR on the NASDAQ.